AP2014008137A0 - Camsylate salt - Google Patents

Camsylate salt

Info

Publication number
AP2014008137A0
AP2014008137A0 AP2014008137A AP2014008137A AP2014008137A0 AP 2014008137 A0 AP2014008137 A0 AP 2014008137A0 AP 2014008137 A AP2014008137 A AP 2014008137A AP 2014008137 A AP2014008137 A AP 2014008137A AP 2014008137 A0 AP2014008137 A0 AP 2014008137A0
Authority
AP
ARIPO
Prior art keywords
camsylate salt
camsylate
salt
Prior art date
Application number
AP2014008137A
Other languages
English (en)
Inventor
Craig Robert Stewart
Martin Hans Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AP2014008137A0 publication Critical patent/AP2014008137A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2014008137A 2012-06-21 2013-06-20 Camsylate salt AP2014008137A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Publications (1)

Publication Number Publication Date
AP2014008137A0 true AP2014008137A0 (en) 2014-12-31

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2014008137A AP2014008137A0 (en) 2012-06-21 2013-06-20 Camsylate salt
AP2017009693A AP2017009693A0 (en) 2012-06-21 2013-06-20 Camsylate salt

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2017009693A AP2017009693A0 (en) 2012-06-21 2013-06-20 Camsylate salt

Country Status (42)

Country Link
US (1) US10548882B2 (en:Method)
EP (2) EP3064494A1 (en:Method)
JP (2) JP2015520221A (en:Method)
KR (1) KR102123708B1 (en:Method)
CN (2) CN106279102A (en:Method)
AP (2) AP2014008137A0 (en:Method)
AR (2) AR091495A1 (en:Method)
AU (2) AU2013279109B2 (en:Method)
BR (2) BR112014031531B1 (en:Method)
CA (1) CA2875589C (en:Method)
CL (1) CL2014003374A1 (en:Method)
CO (1) CO7151486A2 (en:Method)
CR (2) CR20140571A (en:Method)
CY (1) CY1119505T1 (en:Method)
DK (1) DK2864316T3 (en:Method)
DO (1) DOP2014000268A (en:Method)
EC (1) ECSP14032215A (en:Method)
ES (1) ES2618939T3 (en:Method)
HR (1) HRP20170359T1 (en:Method)
HU (1) HUE033376T2 (en:Method)
IL (1) IL236131A0 (en:Method)
IN (1) IN2014DN10088A (en:Method)
LT (1) LT2864316T (en:Method)
MA (2) MA39259B1 (en:Method)
ME (1) ME02633B (en:Method)
MX (1) MX354214B (en:Method)
NI (1) NI201400146A (en:Method)
NZ (2) NZ727045A (en:Method)
PE (1) PE20150670A1 (en:Method)
PH (2) PH12014502803B1 (en:Method)
PL (1) PL2864316T3 (en:Method)
PT (1) PT2864316T (en:Method)
RS (1) RS55815B1 (en:Method)
RU (1) RU2638175C2 (en:Method)
SG (1) SG11201407934UA (en:Method)
SI (1) SI2864316T1 (en:Method)
SM (1) SMT201700142T1 (en:Method)
TN (1) TN2014000491A1 (en:Method)
TW (2) TWI588140B (en:Method)
UA (1) UA114196C2 (en:Method)
WO (1) WO2013190302A1 (en:Method)
ZA (1) ZA201500408B (en:Method)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
AR102202A1 (es) 2014-10-07 2017-02-08 Astrazeneca Ab Compuestos de oxazol y su uso como inhibidores de bace de oxazol
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
CN109195630A (zh) * 2016-03-15 2019-01-11 阿斯利康(瑞典)有限公司 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
CA3131753A1 (en) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE445399T1 (de) 2004-03-22 2009-10-15 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) * 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
JP2009521488A (ja) 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pkc−シータのインヒビターとして有益なピリミジン誘導体
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2008092877A2 (en) 2007-02-01 2008-08-07 Glaxo Group Limited 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
EP2155737A1 (en) 2007-05-07 2010-02-24 Schering Corporation Gamma secretase modulators
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
KR20110048491A (ko) 2008-07-28 2011-05-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스피로아미노디하이드로티아진 유도체들
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2736130C (en) 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
BRPI1009333B8 (pt) 2009-03-13 2021-05-25 Boehringer Ingelheim Int compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
UY32750A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ,インコーポレイテッド ベータセクレターゼインヒビター
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
WO2012040641A2 (en) 2010-09-24 2012-03-29 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
AR083953A1 (es) 2010-11-22 2013-04-10 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
ES2618939T3 (es) 2017-06-22
PH12014502803A1 (en) 2015-02-23
MA37666B1 (fr) 2016-12-30
UA114196C2 (uk) 2017-05-10
KR20150023388A (ko) 2015-03-05
JP2015520221A (ja) 2015-07-16
RU2014148305A (ru) 2016-08-10
AR105176A2 (es) 2017-09-13
CL2014003374A1 (es) 2015-02-27
MX354214B (es) 2018-02-19
AP2017009693A0 (en) 2017-01-31
HK1206349A1 (en) 2016-01-08
KR102123708B1 (ko) 2020-06-16
JP2018104448A (ja) 2018-07-05
PE20150670A1 (es) 2015-06-03
DOP2014000268A (es) 2015-04-15
RU2638175C2 (ru) 2017-12-12
MX2014014709A (es) 2015-03-04
AU2013279109B2 (en) 2017-08-31
CN106279102A (zh) 2017-01-04
EP2864316A1 (en) 2015-04-29
PH12016500498A1 (en) 2017-04-10
ECSP14032215A (es) 2015-12-31
LT2864316T (lt) 2017-03-27
EP2864316B1 (en) 2016-12-14
TWI588140B (zh) 2017-06-21
SI2864316T1 (sl) 2017-04-26
WO2013190302A1 (en) 2013-12-27
IL236131A0 (en) 2015-02-01
CN104411697A (zh) 2015-03-11
MA39259B1 (fr) 2018-09-28
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
DK2864316T3 (en) 2017-03-20
TW201730177A (zh) 2017-09-01
CO7151486A2 (es) 2014-12-29
ZA201500408B (en) 2016-10-26
PH12014502803B1 (en) 2015-02-23
JP6509393B2 (ja) 2019-05-08
BR122016014302B1 (pt) 2022-08-23
TWI639591B (zh) 2018-11-01
TW201406745A (zh) 2014-02-16
BR112014031531B1 (pt) 2022-08-02
HRP20170359T1 (hr) 2017-05-05
BR112014031531A2 (pt) 2017-06-27
NZ702742A (en) 2016-12-23
ME02633B (me) 2017-06-20
BR122016014302A2 (pt) 2019-08-27
AR091495A1 (es) 2015-02-11
CR20140571A (es) 2015-02-04
SG11201407934UA (en) 2015-01-29
MA39259A1 (fr) 2017-12-29
RS55815B1 (sr) 2017-08-31
AU2017254965A1 (en) 2017-11-23
US10548882B2 (en) 2020-02-04
MA37666A1 (fr) 2016-04-29
TN2014000491A1 (en) 2016-03-30
AU2017254965B2 (en) 2019-05-09
HUE033376T2 (en) 2017-11-28
CN104411697B (zh) 2016-08-10
CY1119505T1 (el) 2018-03-07
CR20160202A (es) 2016-07-26
EP3064494A1 (en) 2016-09-07
PT2864316T (pt) 2017-02-24
SMT201700142T1 (it) 2017-05-08
NI201400146A (es) 2016-09-21
CA2875589C (en) 2020-08-25
US20140031379A1 (en) 2014-01-30
IN2014DN10088A (en:Method) 2015-08-21
NZ727045A (en) 2018-06-29
PL2864316T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
ZA201500408B (en) Camsylate salt
GB201204125D0 (en) Compounds
SI2836495T1 (sl) Spojine tetrahidropirolotiazina
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
GB201209096D0 (en) Compounds
HUE036428T2 (hu) Sóhelyettesítõ
GB201219820D0 (en) Compounds
IL239281A0 (en) Dihydrochloride salt of cubicistat
GB201217310D0 (en) Compounds
PL2760822T3 (pl) Sole desfezoterodyny
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218776D0 (en) Compounds